Shares of Curaleaf Holdings, Inc. (OTCMKTS:CURLF - Get Free Report) saw an uptick in trading volume on Tuesday . 1,541,046 shares changed hands during trading, an increase of 112% from the previous session's volume of 726,477 shares.The stock last traded at $2.84 and had previously closed at $2.76.
Wall Street Analyst Weigh In
Separately, Cormark raised Curaleaf from a "hold" rating to a "moderate buy" rating in a research note on Friday.
View Our Latest Stock Report on CURLF
Curaleaf Price Performance
The company has a current ratio of 1.41, a quick ratio of 0.70 and a debt-to-equity ratio of 1.08. The stock has a market cap of $1.89 billion, a P/E ratio of -8.80 and a beta of 0.69. The business has a 50-day simple moving average of $1.11 and a 200 day simple moving average of $1.06.
Curaleaf (OTCMKTS:CURLF - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.06) earnings per share for the quarter, beating analysts' consensus estimates of ($0.07) by $0.01. Curaleaf had a negative net margin of 18.08% and a negative return on equity of 14.41%. On average, analysts forecast that Curaleaf Holdings, Inc. will post -0.25 earnings per share for the current year.
Curaleaf Company Profile
(
Get Free Report)
Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Curaleaf, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Curaleaf wasn't on the list.
While Curaleaf currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.